Hims, Ozempic and Wegovy and Shortage

Ozempic and Wegovy shortage ends, setting up weight loss drug showdown
Ozempic and Wegovy, the popular GLP-1 drugs for diabetes and weight loss, are no longer in short supply, the FDA declared Friday. Why it matters: That's good news for Novo Nordisk (whose stock rose 5% Friday) and potentially bad news for Hims & Hers (which fell 26%).
Hims & Hers warns it may stop selling compounded weight loss drugs
Hims & Hers said on Monday that it may no longer be able to sell compounded versions of the weight-loss drug made by Novo Nordisk because its pathway to do so closed when the U.S. FDA declared Friday that the drug's shortage was over.
Hims & Hers Stock Drops as FDA Says Ozempic and Wegovy No Longer in Short Supply
Key Takeaways Hims & Hers Health shares swooned after the Food & Drug Administration said the active ingredient in Ozempic and Wegovy is no longer in short supply.The company makes compounded versions of weight-loss drugs under an FDA rule that applies when the originals are difficult to obtain.
FDA announces end to Wegovy and Ozempic drug shortages, but it could mean higher prices
The FDA has announced that the shortage of Wegovy and Ozempic, medications used for weight loss and diabetes management, is over.
Hims Stock Crashes After FDA Resolves Weight-Loss Drugs Shortage
Hims stock dropped sharply Friday after the U.S. Food and Drug Administration said the shortage of widely-used weight-loss and diabetes drugs has been resolved. The FDA website indicated that the shortage of Novo Nordisk's Ozempic and Wegovy has ended.
Ozempic and Wegovy are no longer in shortage, FDA says
Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration said on Friday.The update about the popular<a class="excerpt-read-more" hre
Hims & Hers Stock Plummets. The Wegovy Shortage Is Over.
The telehealth company has been selling a copycat version of a popular obesity drug during the recent shortage.
Hims & Hers shares tumble 18% as margin miss adds to concerns about GLP-1 business
Hims & Hers Health reported fourth-quarter results on Monday that beat analysts’ expectations, but the stock sank in extended ...
Wegovy, Ozempic shortage declared over, hitting copycats like Hims & Hers
The ruling shows Novo Nordisk’s confidence that the supply of semaglutide will be stable for now.
Hims & Hers Shares Sink Despite Upbeat Earnings, Outlook
Shares of Hims & Hers Health fell, dragged down by expectations that the telehealth-consultation platform will have to stop selling its weight-loss treatments, which boosted results in the fourth ...
Shortage of popular drugs Wegovy and Ozempic is over, FDA says.
The FDA said the shortage of Novo Nordisk's weight-loss drugs Wegovy and Ozempic is resolved. The move could limit cheaper ...
FDA says Ozempic shortage is over, chilling boom in off-brand versions
The FDA has now resolved the shortages of Novo Nordisk’s and Eli Lilly’s blockbuster weight-loss drugs, which could spell the ...
Hims & Hers Health 4Q Revenue Surges on Boost From Weight-Loss Treatments
Revenue excluding its GLP-1 offering increased 43% to $1.2 billion in 2024 from a year earlier, said Chief Financial Officer Yemi Okupe. Including sales of its weight-loss treatments, revenue surged ...
Ozempic and Wegovy officially moved off FDA’s drug shortage list
Ozempic and Wegovy, the widely popular forms of semaglutide sold to treat diabetes and obesity, have officially been removed ...
Why Hims & Hers Health Stock Is Plummeting Today
Shares of Hims & Hers Health ( HIMS -25.79%) are falling on Friday. The company's stock lost 23.2% as of 1 p.m. ET and lost ...
The Ozempic Shortage Is Over
The semaglutide shortage has officially ended in the US—which means the GLP-1 drug industry is about to undergo massive ...
24/7 Wall St. on MSN3d
Hims & Hers (HIMS) Down 21% – Is the GLP-1 Gravy Train Over?
Shares of Hims & Hers Health (NYSE:HIMS) are down about 21%, or $14. All on news the Ozempic shortage is over. Key Points ...